Synageva BioPharma announces active Investigational New Drug application for SBC-103 for the treatment of MPS IIIB

Synageva BioPharma announces active Investigational New Drug application for SBC-103 for the treatment of MPS IIIB. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data in 2015. Read the full press release for more information.

This entry was posted in News. Bookmark the permalink.

Comments are closed.